Abstract
Metastasis to the bone is most frequently observed in advanced cases of breast and prostate cancer. The latent development of overt metastatic lesions is associated with debilitating skeletal morbidity and eventual patient mortality. Secondary tumours in bone are derived from disseminated tumour cells (DTCs) that enter into a state of cellular dormancy. The dormant state confers resistance to conventional chemotherapeutic agents and prevents elimination of DTCs from the bone using current drug therapies. Expansion of our presently limited understanding of the molecular mechanisms underpinning disseminated breast and prostate tumour cell dormancy is critical to the future development of novel drug therapies aimed at the removal of DTCs, and thereby, the prevention of bone metastasis. This review provides an overview of the main putative molecular mechanisms underlying cellular dormancy in breast and prostate cancer bone metastasis reported from multiple experimental in vitro and in vivo models.
Keywords: Bone metastasis, breast, cancer, disseminated tumour cells, dormancy, prostate, quiescence.
Graphical Abstract
Current Cancer Drug Targets
Title:Bone Metastasis: Molecular Mechanisms Implicated in Tumour Cell Dormancy in Breast and Prostate Cancer
Volume: 15 Issue: 6
Author(s): Lewis Quayle, Penelope D. Ottewell and Ingunn Holen
Affiliation:
Keywords: Bone metastasis, breast, cancer, disseminated tumour cells, dormancy, prostate, quiescence.
Abstract: Metastasis to the bone is most frequently observed in advanced cases of breast and prostate cancer. The latent development of overt metastatic lesions is associated with debilitating skeletal morbidity and eventual patient mortality. Secondary tumours in bone are derived from disseminated tumour cells (DTCs) that enter into a state of cellular dormancy. The dormant state confers resistance to conventional chemotherapeutic agents and prevents elimination of DTCs from the bone using current drug therapies. Expansion of our presently limited understanding of the molecular mechanisms underpinning disseminated breast and prostate tumour cell dormancy is critical to the future development of novel drug therapies aimed at the removal of DTCs, and thereby, the prevention of bone metastasis. This review provides an overview of the main putative molecular mechanisms underlying cellular dormancy in breast and prostate cancer bone metastasis reported from multiple experimental in vitro and in vivo models.
Export Options
About this article
Cite this article as:
Quayle Lewis, Ottewell D. Penelope and Holen Ingunn, Bone Metastasis: Molecular Mechanisms Implicated in Tumour Cell Dormancy in Breast and Prostate Cancer, Current Cancer Drug Targets 2015; 15 (6) . https://dx.doi.org/10.2174/1568009615666150506092443
DOI https://dx.doi.org/10.2174/1568009615666150506092443 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Natural Tumor Suppressor Protein Maspin and Potential Application in Non Small Cell Lung Cancer
Current Pharmaceutical Design Neuropeptide Y and Cancer Anorexia
Current Medicinal Chemistry - Central Nervous System Agents MicroRNAs in Esophageal Adenocarcinoma: Functional Significance and Potential for the Development of New Molecular Disease Markers
Current Pharmaceutical Design Protein-Modified Magnetic Nanoparticles for Biomedical Applications
Current Organic Chemistry Ganoderma lucidum: A Potent Pharmacological Macrofungus
Current Pharmaceutical Biotechnology Subject Index to Volume 4
Current Drug Metabolism Overexpression of Nemo-like Kinase Promotes the Proliferation and Invasion of Lung Cancer Cells and Indicates Poor Prognosis
Current Cancer Drug Targets Generation of Human Single-chain Antibody to the CD99 Cell Surface Determinant Specifically Recognizing Ewing’s Sarcoma Tumor Cells
Current Pharmaceutical Biotechnology Preparation and physicochemical characterization of inclusion complexes derived from phytosterols and β-cyclodextrin
Letters in Organic Chemistry Leptin as a Cardiac Pro-Hypertrophic Factor and its Potential Role in the Development of Heart Failure
Current Pharmaceutical Design Reconstruction, Topological and Gene Ontology Enrichment Analysis of Cancerous Gene Regulatory Network Modules
Current Bioinformatics KCa3.1 Channels and Glioblastoma: In Vitro Studies
Current Neuropharmacology Drug Target Identification for Neuronal Apoptosis Through a Genome Scale Screening
Current Medicinal Chemistry Synthesis of Novel Imine Stilbene Analogs Exhibiting Potent Anticancer Activity
Anti-Cancer Agents in Medicinal Chemistry Genetics Talks to Epigenetics? The Interplay Between Sequence Variants and Chromatin Structure
Current Genomics Hepatobiliary Diseases and Insulin Resistance
Current Medicinal Chemistry Neuropeptidomics: Improvements in Mass Spectrometry Imaging Analysis and Recent Advancements
Current Protein & Peptide Science Advances and Challenges in the Use of Nanoparticles to Optimize PK/PD Interactions of Combined Anti-Cancer Therapies
Current Drug Metabolism Systems Biology and Personalized Medicine in Cancer
Current Pharmacogenomics and Personalized Medicine Development of a Web-Enabled SVR-Based Machine Learning Platform and its Application on Modeling Transgene Expression Activity of Aminoglycoside-Derived Polycations
Combinatorial Chemistry & High Throughput Screening